NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AlivaMab Biologics

AlivaMab Biologics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://alivamab.com/

Last Round

Seed

May 1, 2018

Momentum

Top 1%

of companies Caplight tracks

Company Overview

AlivaMab Biologics is a drug discovery company that provides fully integrated solutions for biologics drug discovery through its platform of innovative capability modules.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

contract research organizationantibody discoveryCROtransgenic mouse platformfully human antibodiesantibody engineeringbiologics CRObiologics drug discoveryfee-for-servicehumanized mouse modelsoutsourced R&Dbispecific antibodiesCAR engineeringGPCR targetsdevelopability assessmenthigh-throughput screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AlivaMab Biologics Comparables

Compare AlivaMab Biologics with similar companies based on industry and business-model similarity.

AlivaMab Biologics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AbTherx, Inc.
86%
Alloy Therapeutics
80%
Ablexis
80%

AlivaMab Biologics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 1, 2018

Key People

Founding team and executive leadership

Larry Green

Chief Executive Officer

Executive Team

Hans Lundin

Fractional CFO

Executive Team

AlivaMab Biologics Investors

Notable investors and investment history

AlivaMab Biologics investors
InvestorRounds
Deerfield ManagementSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 24, 73% of headcount.

  • Jul 5, 2025

    Monthly visitors increased 42% MoM.

AlivaMab Biologics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AlivaMab Biologics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AlivaMab Biologics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range33
Year Founded2018
Last FundingMay 1, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.